GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

In 2021, GSK and Oxford established the Institute of Molecular and Computational Medicine to drive forward the research and ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold. Pharmaceutical giant GSK and the University of Oxford have partnered to ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

GSK has claimed its second breakthrough designation ... stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the drug for this use last year.

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...